PubMed
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves neuropathic symptoms in patients with sarcoidosis
Dahan A, Dunne A, Swartjes M, et al. Mol Med. 2013
Compare
ARA-290 vs Pentosan Polysulfate
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
ARA-290
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 33% · Mixed 67% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
4
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
2+ mg
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Pentosan Polysulfate
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 0% · Mixed 17% · Unfavorable overall 83%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Digestive upset
6
Self-reported dose per injection
Median bucket: 0–25 mcg · Most common: 0–25 mcg
Reports cluster around 0–25 mcg
0–25
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Sources (7)
Published sources linked on the ARA-290 and Pentosan Polysulfate wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
ARA 290 for treatment of small fiber neuropathy in sarcoidosis
van Velzen M, Heij L, Niesters M, et al. Expert opinion on investigational drugs. 2014
- Wiki study page →Source
PubMed
The time to develop treatments for diabetic neuropathy
Rendell MS. Expert opinion on investigational drugs. 2021
- Wiki study page →Source
FDA Drug Label
ELMIRON (pentosan polysulfate sodium) — Prescribing Information
Janssen Pharmaceuticals. FDA Drug Label. 1996
- Wiki study page →Source
PubMed
Pentosan polysulfate sodium for knee osteoarthritis: systematic review
Bannuru RR, Osani MC, Vaysbrot EE, et al. Osteoarthritis Cartilage. 2020
- Wiki study page →Source
PubMed
New therapeutic strategies in osteoarthritis
Siddiq MAB, Oo WM, Hunter DJ. Joint bone spine. 2024
- Wiki study page →Source
PubMed
The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment
Ghosh P. Seminars in arthritis and rheumatism. 1999